Clinical Trials in Atlanta

Showing 19781-19800 of 19,805 trials

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

NCT00002187

The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis

Cytomegalovirus RetinitisHIV Infections

Ionis Pharmaceuticals, Inc.

Los Angeles, California, United States • Pasadena, California, United States • San Francisco, California, United States +14 more locations

COMPLETEDPhase 2< 1 mile

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

NCT00002265

To demonstrate that zalcitabine (dideoxycytidine; ddC) monotherapy is safe and tolerable in the treatment of patients with AIDS or advanced AIDS related complex (ARC) who previously demonstrated intolerance to zidovudine (AZT) treatment while in Protocol N3300 (NIAID ACTG 114) or N3492 (NIAID ACTG 119). NOTE OF CAUTION FOR CONCOMITANT MEDICATIONS ON STUDY: Patients on amphotericin, pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole, ganciclovir, intravenous pentamidine, intravenous acyclovir or oral acyclovir or other bone marrow or renal toxic drugs may not tolerate concomitant ddC. If these drugs are given concomitantly with ddC, patients should have frequent clinical and laboratory assessments, as appropriate. Drugs that are nephrotoxic or have the potential to cause peripheral neuropathy might be expected to cause increased toxicity when co-administered with ddC. Drugs that could cause serious additive toxicity when co-administered with study medication will be allowed for treatment of an acute intercurrent illness or opportunistic infection at the discretion of the investigator. Their use may be allowed with interruption of study drug for up to 35 days per episode, for a total of 90 days for the study. If the patient's condition requires chronic administration of these medications, the patient will be discontinued from study medication and followed.

HIV Infections

Hoffmann-La Roche

San Francisco, California, United States • San Francisco, California, United States • Fort Lauderdale, Florida, United States +6 more locations

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

Find Trials by Condition in Atlanta

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

A "Pre-Enrollment" Protocol for HIV-Infected Adolescents

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Trial of VLTS-589 in Subjects With Intermittent Claudication

Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

A Study to Compare Two Anti-HIV Drug Combinations

Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

A Study of DTC in Patients With AIDS and AIDS Related Complex

A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin

Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.